February 20, 2017
New Data Demonstrate that Synaffix ADCs Significantly Expand the Therapeutic Index vs Cysteine-Engineered ADCs
Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced a new set of head-to-head data, that demonstrates the potential of its technology to significantly expand the therapeutic index vs cysteine-engineered ADCs.
read more »
January 17, 2017
Bird Rock Bio Receives Approval to Start First in Human Clinical Trial for Namacizumab, Enters Into Agreement with GE Healthcare for Process Development and Scale-up to Provide Clinical Phase 2 cGMP Material
and enters into a Collaboration and Option Agreement with Janssen Pharmaceuticals, Inc.
Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, announced today that it has received approval for the initiation of a two-part Phase 1 clinical trial for namacizumab, a novel therapeutic antibody to the cannabinoid 1 receptor (CB1). In addition, Bird Rock Bio has entered into an agreement with GE Healthcare for process development, formulation, and manufacture of namacizumab in preparation for Phase 2 studies. Furthermore, the Phase 1 trial, process development, and Phase 2 preparation will be funded under a collaboration and option agreement with Janssen Pharmaceuticals, Inc.
read more »